会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • FORMULATIONS AND METHODS FOR TREATING HIGH INTRAOCULAR PRESSURE
    • 用于治疗高眼压的制剂和方法
    • WO2017066052A1
    • 2017-04-20
    • PCT/US2016/055404
    • 2016-10-05
    • BRIDGE PHARMA, INC.
    • ABERG, A. K. GunnarCIOFALO, Vincent B.JOHNSON, Keith
    • A61K31/4535A61K9/00A61P27/06
    • A61K31/4535A61K9/0043A61K9/0048A61K9/06A61K9/08A61K9/107A61K45/06A61K47/10A61K47/183A61K47/26
    • Disclosed herein are methods of treating a mammal in need of a reduction in intraocular pressure by administering an intraocular formulation including a therapeutically effective amount of norketotifen for the reduction of intraocular pressure to the eye of the mammal in need thereof, wherein the intraocular formulation includes about 0.02 wt% to about 1.0 wt% norketotifen or a salt or an isomer thereof, calculated as the norketotifen free base. In certain aspects, the intraocular formulation is free from any added preservative and the intraocular formulation is self-preserving. Also included herein is a method of treating a human in need of a reduction in intraocular pressure by administering an intranasal formulation that includes a therapeutically effective amount of norketotifen for the reduction of intraocular pressure to the eye of the human in need thereof. Also, the beneficial effects of known drugs for high IOP are improved by co-administration with norketotifen.
    • 本文公开了治疗需要降低眼内压的哺乳动物的方法,其通过施用包含治疗有效量的诺酮替哌的眼内制剂用于将眼内压降低至有需要的哺乳动物的眼睛 其中所述眼内制剂包含约0.02重量%至约1.0重量%的诺卡替芬或其盐或其异构体,以诺酮替芬游离碱计算。 在某些方面,眼内制剂不含任何添加的防腐剂,并且眼内制剂是自我保存的。 本文还包括通过施用鼻内制剂来治疗需要降低眼内压力的人的方法,所述鼻内制剂包含治疗有效量的诺酮替哌,用于将眼内压降低至有需要的人的眼睛。 此外,已知药物对于高IOP的有益效果通过与诺卡替芬共同施用而得到改善。